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Novel Mutations in X-Linked Dominant Chondrodysplasia
Punctata (CDPX2)
To the Editor:
X-linked dominant chondrodysplasia punctata (CDPX2;
MIM302960), also known as Conradi^Hˇnermann^Happle syn-
drome, is characterized by skeletal abnormalities including short
stature, asymmetric rhizomelic shortening of the limbs, epiphy-
seal stippling, and craniofacial defects (Happle, 1979). In addition,
there are transient skin defects including striated palmoplantar
hyperkeratosis, follicular atrophoderma, and pigmentary defects
in patterns following the lines of Blaschko that can resolve
during early infancy. Unilateral or segmental cataracts can also
be present and the hair is coarse and lusterless with areas of scar-
ring alopecia. The clinical phenotype of CDPX2 is variable, ran-
ging from stillborn or lethal forms, to mild, almost clinically
undetectable forms.The disease is usually lethal in male embryos,
although surviving cases have been reported (Milunsky et al,
2001; Diaz et al, 2002).
Genetic counseling can prove di⁄cult because there can be a
stepwise increase in disease expression from one generation to
the next (anticipation) in some families (Traupe et al, 1992;
Sutphen et al, 1995). Biochemical studies on CDPX2 patients
demonstrated increased amounts of 8-dehydrocholesterol and 8(9)-
cholestenol in the plasma and tissues (Kelley et al, 1999), and sub-
sequent molecular studies demonstrated that CDPX2 was caused
by mutations in the human emopamil-binding protein gene, EBP
(Braverman et al, 1999; Derry et al, 1999), which was mapped to
Xp11.23-p11.22 (Hanner et al, 1995; Schindelhauer et al, 1996). The
gene comprises ¢ve exons, four of which encode a 230-amino-
acid, four-transmembrane domain protein that functions as a
D8^D7 sterol isomerase with a predicted molecular weight of 27
kDa (Hanner et al, 1995; Silve et al, 1996). Further screening of EBP
has identi¢ed additional mutations in females with CDPX2 (Has
et al, 2000; Ikegawa et al, 2000; Becker et al, 2001; Herman et al,
2002; O⁄ah et al, 2003;Whittock et al, 2003) as well as a case of
CDPX2 erroneously classi¢ed as CHILD syndrome (Grange et al,
2000).
Here, we have studied 11 unrelated individuals with CDPX2.
Cases 1 and 6 have previously been reported by us (O⁄ah et al,
2003; Whittock et al, 2003). Plasma sterols from patients and re-
lated individuals were analyzed as described previously (Clayton
et al, 1993; FitzPatrick et al, 1998), and exons 2^5 of the human
EBP gene were directly ampli¢ed from genomic DNA as pre-
viously described (Whittock et al, 2003). All patients presented
with a distinctive phenotype a¡ecting skeletal, skin, eye, and hair
development (Fig 1,Table I). All but 2 cases presented with short
stature and asymmetrical shortening of the limbs. Of the excep-
tions, case 1 has normal stature, clinodactyly, and no evidence of
limb asymmetry, and case 2 shows no evidence of short stature
although limb asymmetry and hypoplasia of the vertebral bodies
is present. All live-born individuals had hyperkeratosis and pat-
chy ichthyotic skin following the lines of Blaschko. The hair
was sparse, ¢ne, and dry in all cases, and there was evidence of
cicatricial alopecia in all but one case. In 6 patients there was evi-
dence of unilateral or bilateral cataracts as well as two ¢ndings of
optic nerve hypoplasia (cases 3 and 10). Two individuals presented
with nail dystrophy (cases 1 and 10), 1 individual had a hearing
loss (case 4), and all individuals were of normal intelligence. Ter-
mination of pregnancy was performed for case 6 owing to the
detection of skeletal malformations during routine ultrasound.
We found markedly elevated levels of 8(9)-cholestenol and 8-de-
hydrocholesterol compared with controls in all but 1 patient af-
fected with CDPX2. The exception (case 8) revealed normal
levels of 8(9)-cholestenol and 8-dehydrocholesterol and addi-
tional sterol analysis of ¢broblasts from a skin biopsy taken from
the left arm at an area of follicular atrophoderma also showed
normal levels of 8(9)-cholestanol, thus clearly illustrating the pro-
blems in assessing cholesterol biosynthesis in a clonal population
of cells.
Mutations were characterized in EBP for all individuals (Table
I) including seven novel mutations at the nucleotide level,
namely 36 G4A (W12X), 111delTG, 197T4C (L66P), 204G4A
(W68X), IVS2þ1delGT, 440del4, and D162H, a¡ecting exons 2,
4, and 5. At the protein levelW68X has previously been reported
but is due to a mutation in an alternative nucleotide in codon 68
(203G4A) (Has et al, 2000). Two mutations have previously been
described by us, namely 399C4A (S133R) (Whittock et al, 2003)
and 552C4G (Y184X) (O⁄ah et al, 2003).We have also detected
two recurrent mutations. The arginine to histidine missense mu-
tation (R147H) appears to be a frequent mutation as it has been
described in patients originating from America (Braverman et al,
1999; Herman et al, 2002), Japan (Ikegawa et al, 2000), and Europe
(Has et al, 2002), whereas the nonsense mutation R63X has been
detected in America (Derry et al, 1999; Braverman et al, 1999;
Herman et al, 2002) and Europe (Has et al, 2000). This increases
the mutations characterized to date to 53, including 2 mutations
characterized in males (Milunsky et al, 2001; Diaz et al, 2002)
(Fig 2). We have also demonstrated that at least 4 mutations
occurred de novo. However, although not proved using molecular
diagnosis, there is also evidence of gonadal mosaicism in cases 1,
5, and 10.The suggestive evidence in these cases is a bias of female
pregnancies and the presence of miscarried male pregnancies
(pedigree data not shown).
An important clinical observation in this study is that a¡ected
female individuals had normal mental development despite the
fact that virtually all cholesterol in the brain is synthesized de novo
(Woollett, 2001). The question therefore arises as to whether de-
fective-X inactivated cells synthesize enough cholesterol to com-
pensate for the normal X-inactivated cells in a¡ected females? It
is clear that defective cells themselves cannot produce enough de
novo cholesterol in the brain as surviving males with defects
in delta(8)-delta(7) sterol isomerase are severely handicapped
(Milunsky et al, 2001; Diaz et al, 2002). Therefore, it can be con-
cluded that the amount of cholesterol required for the normal de-
velopment of the brain in a¡ected females must arise mainly
from the normal X-inactivated cells.
Reprint requests to: Dr Neil V Whittock, Molecular Genetics Labora-
tory, Royal Devon and Exeter Hospital, Old Pathology Building, Barrack
Road, Exeter EX2 5DW, UK. Email: nwhittoc@hgmp.mrc.ac.uk
Abbreviations: EBP, emopamil-binding protein gene.
Manuscript received March 25, 2003; revised April 24, 2003; accepted for
publication April 25, 2003
0022-202X/03/$15.00 . Copyrightr 2003 by The Society for Investigative Dermatology, Inc.
939
LETTERTO THE EDITOR
See related Editorial on page v
Figure1. Clinical appearance of proband 10, a¡ected by X-linked dominant chondrodysplasia punctata. (a) Asymmetric facial appearance, show-
ing coarse, sparse hair, undirected growth of eyebrows with sparse lateral growth, a £at nasal bridge, bilateral epicanthus, and strabismus. (b) Cicatricial
alopecia and sparse irregular hair growth and premature graying. (c) Short ¢ngers, with ¢fth ¢nger clinodactyly and short-terminal phalanx left ¢fth ¢nger.
(d) Right mild two-thirds toe syndactyly, toenail dystrophy, and hyperkeratosis.
Figure 2. Mutations in CDPX2. Schematic diagram of the emopamil-binding protein with the mutations characterized to date.
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In summary, we show that gas chromatography^mass spec-
trometry determination of cholesterol precursors in serum is
a valuable tool in the diagnosis of CDPX2. However, where
possible, direct sequencing of the EBP gene should also be
performed to con¢rm the diagnosis as sterol pro¢ling can
occasionally be misleading. Neither sterol pro¢les nor muta-
tions can give an indication of the severity of the clinical
phenotype.
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Table I. Clinical, sterol, and molecular analysis of the CDPX2 patientsa
Case
1 2 3 4 5 6b 7 8 9 10 11
Origin Albania UK UK UK UK UK Turkish UK UAE UK UK
Age (y) 31 26 2 17 3 Fetus 2 25 1 38 2
Family history No No Yes Yes No No No No No No No
Skeletal features
Short stature No Yes Yes Yes Yes Yes Yes Yes Yes No
Asymmetrical
limb shortening
No Yes Yes Yes Yes N/A No Yes Yes Yes Yes
Scoliosis No Yes Yes No Yes









Cataracts No Right Leftþ right Right No Right Leftþ right Right Left No
Optic nerve
hypoplasia
No No Unilateral No No No No No Unilateral No
Skin features N/A
Patchy ichthyosis Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes




Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Cicatricial alopecia Yes Yes Yes Yes No Yes Yes Yes Yes Yes




Intelligence Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal




5.64 0.91 4.52 1.50 6.50 2.94
(0.5^3.0)
2.08 1.34 3.55 0.53 1.87
Lathosterol
(0.53^15.98)
13.85 3.67 2.68 4.07 6.26 6.37
(1^20)
1.39 3.81 1.56 4.38 5.83
Cholestanol
(3.87^18.04)
18.14 4.42 3.89 4.72 5.41 2.0 (NM) 2.39 5.29 10.82 1.38 2.11




38.95 16.88 30.99 18.6 30.3 5.88 (o1.0) 13.2 0.25 19.85 23.45 27.6
8-DHC (o 2.0) 16.95 7.99 12.54 4.23 7.84 0.64 (o0.3) 44.0 1.39 45.13 6.83 8.3
Exon 4 5 2 2 4 5 4 2 2 2 2
Mutationc 399C4A 484G4C 197T4C 111delTG 440del4 552C4G 440G4A 187C4T 36G4A 204G4A IVS2þ1delGT
Protein domain TM 3 ER 2 TM 2 TM 1 ER 2 TM 4 ER 2 ER 1 N-term TM 2 Cytoplasmic
Protein change S133R D162H L66P fs fs Y184X R147H R63X W12X W68X Splicing
aSterol concentrations in plasma are measured in mM. ND, not detected; NM, not measured; N/A, not applicable; TM, transmembrane; ER, endoplasmic reticulum
loop; fs, frameshift.
bMuscle sterol pro¢le of fetus expressed as ratio to cholesterol (mM/mM).
cMutations in bold represent novel mutations.
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